Objective: To analysis the expression of CD7 in NK/T-cell lymphoma as well as study the correlations between CD7 and clinical survival and prognosis. Methods: The clinical and pathological indicators of 112 NKTCL patients who were admitted to or consulted at the First Affiliated Hospital of Zhengzhou University between May 2008 and December 2019 were analyzed retrospectively. The CD7 expression in the tumor tissues was detected using immunohistochemistry staining, and the influence of CD7 expression on the survival and prognosis in the patients was analyzed. Results: The CD7 expression rate was 84.82% in 112 NKTCL patients, and its expression was not influenced by sex, age, and the primary site. An analysis of the complete clinical data of 72 patients showed that the CD7 expression was significantly correlated with the PINK score, tumor metastasis, and peripheral blood EBV-DNA level. However, the Ann Arbor stage, bone marrow involvement, B symptoms, IPI/aaIPI score, Ki-67, EBER, TIA-1, Granzyme B, LDH, and β(2)-MG were not associated with the CD7 expression. The 1-year, 3-year, and 5-year overall survival (OS) rates of the 72 patients were 81.2%, 61.8%, and 58.8%, respectively, and the progression-free survival (PFS) rates were 53.5%, 29.4%, and 24.0%, respectively. The median overall survival (median-OS, mOS) was 81 mon, and the median progression-free survival (median-PFS, mPFS) was 14 mon. The 3-year OS rates in the CD7-positive group and the CD7-negative group were 58.1% and 83.9%, respectively, (P>0.05) . The 3-year PFS rates were 21.7% and 51.9%, respectively (P<0.05) . The univariate analysis showed that age, primary tumor site, Ann Arbor stage, IPI/aaIPI score, PINK score, LDH, β(2)-microglobulin, EBV-DNA, Ki-67, and CD7 influenced patient prognosis. The multivariate analysis showed that Ann Arbor stage and CD7 were independent prognostic factors for PFS, while PINK score and Ki-67 were independent prognostic factors for OS. Conclusions: The expression rate of CD7 in NKTCL was high and was closely related to poor patient prognosis. The patients with high levels of EBV-DNA, metastatic disease, or high PINK score were more likely to express CD7.
目的： 分析CD7在NK/T细胞淋巴瘤（NKTCL）中的表达情况，并探讨其与生存及预后的相关性。 方法： 回顾性分析2008年5月至2019年12月郑州大学第一附属医院收治或会诊的112例NKTCL患者的病例资料，免疫组织化学染色检测肿瘤组织中CD7的表达情况，分析CD7表达对患者生存及预后的影响。 结果： 112例NKTCL患者中CD7阳性表达率为84.82%，其表达与性别、年龄、原发部位无关。对临床资料完整的72例患者进行分析，结果表明，CD7的表达与PINK评分、肿瘤转移、外周血EBV-DNA水平相关，而分期、骨髓是否受累、有无B症状、IPI/aaIPI评分、Ki-67、EBER、TIA-1、GranzymeB、LDH、β(2)-微球蛋白水平与CD7表达无关。72例患者的生存分析显示，其1、3、5年总生存（OS）率分别为81.2%、61.8%和58.8%，无进展生存（PFS）率分别为53.5%、29.4%和24.0%。中位OS期为81个月，中位PFS期为14个月。CD7阳性组与CD7阴性组的3年OS率分别为58.1%和83.9%（P>0.05），3年PFS率分别为21.7%和51.9%（P<0.05）。单因素分析显示，年龄、原发部位、Ann Arbor分期、IPI/aaIPI评分、PINK评分、LDH水平、β(2)-微球蛋白水平、外周血EBV-DNA、Ki-67的表达水平及CD7表达影响患者预后。多因素分析显示，Ann Arbor分期及CD7表达是PFS的独立预后因素，PINK评分及Ki-67表达水平是OS的独立预后因素。 结论： CD7在NKTCL中的表达率高，且与不良预后密切相关。PINK评分中/高危、外周血EBV-DNA水平高或已出现转移的患者更易表达CD7。.
Keywords: CD7; EBV-DNA; NK/T-cell lymphoma; PINK score; Prognosis.